Figure 5  .

(A) Decrease in serum VEGF concentration after a single infusion of infliximab in a randomised placebo controlled trial of infliximab in RA. Serum VEGF levels were measured by enzyme linked immunosorbent assay in 69 patients with active RA who received a single infusion of either placebo or infliximab (indicated by arrow). Values are the median counts in placebo treated (circle), 1 mg/kg (diamond) and 10 mg/kg (triangle) of infliximab treated patients. Values were expressed as the % change from preinfusion for each patient, before calculation of median changes for each treatment group. Data were analysed by Mann-Whitney U test for comparison between treatment groups († = p < 0.05; †† = p < 0.01; ††† = p < 0.001). p Values for comparisons between multiple groups were adjusted using the Bonferroni correction. (B) Correlation between changes in serum VEGF concentrations and changes in swollen joint scores. Kendall's coefficient of rank correlation, calculated using % change in serum VEGF and swollen joint scores three weeks after infusion of infliximab is 0.245 (p < 0.01). Reproduced with modification from Arthritis Rheum 1998;41:1258-65 by kind permission of the editor.